RxDoctor Payments Data

Jeremy Rowe, PA

Physician Assistant · Toledo, OHNPI 1346568060

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,046 and has fallen 83.2% since, to $175 in 2025.

$1,908in general payments, 2019–2025

Across 74 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$348
  • Johnson & Johnson$342
  • Incyte Corporation$244
  • E.r. Squibb & Sons, L.L.C.$207
  • Galderma Laboratories, L.p.$150
  • Stemline Therapeutics Inc.$125
  • plus $490 from 12 others

What the payments were for

  • Food & beverage$1,74591%
  • Education$1639%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,908 in reported general payments places this provider in the 85th percentile of 4,098 physician assistant providers in Ohio.

See all physician assistant providers in Ohio →

Medicare billing

Part B allowed, 2024
$37,218
Medicare patients
227
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa30$569,846
OtezlaApremilast84$400,734
Dupixent PenDupilumab96$358,057
Humira(Cf) PenAdalimumab19$256,857
Cosentyx Sensoready (2 Pens)Secukinumab19$165,456
Taltz AutoinjectorIxekizumab21$142,900
Cosentyx Unoready PenSecukinumab12$104,248
Clobetasol Propionate282$16,486
Triamcinolone Acetonide337$4,559
Clindamycin Phosphate90$4,459
Ketoconazole247$4,391
Tacrolimus42$4,316
Fluocinonide85$3,914
Metronidazole51$3,432
Tretinoin20$2,509

Paid to pharmacies, not to this prescriber.

Other physician assistant in Toledo

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →